New Report Reveals Alarming Decline in Women’s Cancer Testing Worldwide
21.1.2025 14:00:00 CET | Business Wire | Press release
Women’s cancer testing has declined globally, according to the latest Hologic Global Women’s Health Index, one of the largest collections of data on women’s health and well-being.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121461870/en/
Hologic, Inc. (Nasdaq: HOLX), a leading women’s health innovator, partners with Gallup to create the Index. Now in its fourth year, the Index raises new concerns about declining trends in women’s health. For the first time in the history of the Index, women’s cancer testing declined: Only 10% of women surveyed worldwide said they were tested for any type of cancer in the past year, down two percentage points from the first two years of the Index.
This year’s Index will be released today during an event convened by Goals House, a community focused on driving progress toward the United Nations (UN) Sustainable Development Goals (SDGs) alongside the World Economic Forum in Davos, Switzerland. The event will feature a panel including Dr. Natalia Kanem, Executive Director of the United Nations Population Fund (UNFPA), Dr. Sania Nishtar, CEO, Gavi, The Vaccine Alliance and Elissa Miolene, Global Development Reporter, Devex.
“Today’s data reveal a worsening trend in women’s health,” said Stephen P. MacMillan, Chairman, President and CEO of Hologic. “The shocking decline in cancer testing is a wake-up call. Business as usual is not working. Innovative strategies and collaborative efforts are needed to make sustained improvements in women’s health and well-being around the world.”
Key findings from this year’s Index:
- Cancer Screening Among Women Declined: Only 10% of women said they underwent any type of cancer testing in the past year, reflecting a decrease of two percentage points from the first two years of the survey.
- Women Are Struggling More to Meet Basic Needs: A staggering 38% of women reported being unable to afford food at some point in the past year, marking the highest level of food insecurity in nearly two decades. And 32% of women said they could not afford adequate shelter.
- More Women Are Worried and Sad: More women reported feeling worried (42%) and sad (30%) compared to Year 1 of the Index. And over one third (35%) said they felt unsafe in their communities.
- Ongoing Physical Pain and Health Issues:34% of women reported experiencing significant pain the previous day, while 26% indicated that health problems impacted their ability to engage in everyday activities.
- HIV Testing Rates for Women Are Alarmingly Low: The Index assessed women’s HIV testing for the first time and found concerning disparities: Less than0.5% of women were tested in certain countries, primarily those in the Middle East and North Africa, and no country scored above 41%. Globally, the percentage is much lower. Just 6% of women — regardless of whether they visited a healthcare professional or were tested for STIs — said they were tested for HIV in the past year.
- Signs of Hope — Some Countries Are Making Progress:28 countries saw meaningful increases in their Index scores since the first year of the Index, including Kazakhstan, Kenya, Poland and Venezuela.
The Index assigns a women’s health score to each country or territory based on survey responses on five dimensions of health. Overall, the world scored 53 out of 100 on the Index in Year 4, reflecting no significant change since the Index started.
Taiwan led the world for the fourth consecutive year, scoring 68 out of a possible 100. Other top scores went to Kuwait (67), Austria (66) and Switzerland (65). The lowest scores went to Afghanistan (30), the Democratic Republic of Congo (34) and Chad (35). The United States scored 60 – on par with New Zealand (60) and Lithuania (60) – and fell seven places from its ranking in the third year of the Index to 37 out of 142 countries and territories.
The Index fills a critical gap in knowledge about the health, safety and well-being of women worldwide. Based on interviews with more than 146,000 women and men in 142 countries and territories, it represents the voices of 97% of the world’s women and girls aged 15 and older.
To see the full Index and related resources, visit WomensHealthIndex.com.
About Hologic, Inc.
Hologic, Inc. is a global leader in women’s health, dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.
Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
About Gallup
Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students and citizens than any other organization in the world.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121461870/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom